Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

You'll hear cautious optimism about cardiovascular benefits with the new SGLT2 inhibitor, Jardiance (empagliflozin).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests that Jardiance also reduces CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote